LPAR5 and lung cancer: Taken together, these data indicate that dysregulation of the ATX/LPA/LPAR5 axis contributes to PD-1 blockade therapy resistance in KP mutant lung cancer, and cotargeting this immunosuppressive axis efficaciously controls lung cancer progression and metastasis (Figure 7).